Breaking News Instant updates and real-time market news.

EOLS

Evolus

$23.52

-0.61 (-2.53%)

, COTY

Coty

$10.85

0.01 (0.09%)

08:45
05/03/19
05/03
08:45
05/03/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Evolus (EOLS) 54.47% +1.98, Coty (COTY) 1.70% +1.15, Cenovus Energy (CVE) 0.40% +0.09, Direxion S&P Biotech Bear 3X (LABD) 8.75% +0.05, Ubiquiti (UBNT) 0.43% +0.03, FAS (FAS) 1.05% +0.02, Qutoutiao (QTT) 4.77% +0.02, DexCom (DXCM) 0.27% +0.02, Acadia (ACAD) 0.42% +0.01, and Crispr Therapeutics (CRSP) 1.82% +0.01.

EOLS

Evolus

$23.52

-0.61 (-2.53%)

COTY

Coty

$10.85

0.01 (0.09%)

CVE

Cenovus Energy

$9.11

-0.285 (-3.04%)

LABD

Daily S&P Biotech Bear 3x Shares

$21.93

-0.69 (-3.05%)

UBNT

Ubiquiti

$169.26

-0.48 (-0.28%)

QTT

Qutoutiao

$7.16

0.34 (4.99%)

DXCM

DexCom

$120.35

2.01 (1.70%)

ACAD

Acadia

$25.51

3.4 (15.38%)

CRSP

Crispr Therapeutics

$40.35

0.46 (1.15%)

  • 04

    May

  • 06

    May

  • 08

    May

  • 08

    May

  • 14

    May

  • 20

    May

  • 30

    May

  • 05

    Jun

  • 25

    Jul

  • 13

    Nov

EOLS Evolus
$23.52

-0.61 (-2.53%)

05/01/19
CANT
05/01/19
NO CHANGE
Target $35
CANT
Overweight
Cantor reiterates Overweight on Evolus after 'solid execution' in Q1
Cantor Fitzgerald analyst Louise Chen says Evolus posted a quarter of "solid execution." The analyst continues to think Jeuveau's value proposition is underappreciated and that it will pick up more market share than anticipated. Ahead of what she expects to be a better than expected launch of Jeuveau, Chen reiterates an Overweight rating on Evolus with a $35 price target. , The U.S. and other launches should drive Evolus shares higher, says the analyst.
03/19/19
RHCO
03/19/19
INITIATION
Target $29
RHCO
Buy
Evolus assumed with a Buy at SunTrust
SunTrust transferred coverage of Evolus (EOLS) to analyst Gregg Gilbert, who established a Buy rating and $29 price target on the stock. The analyst cites the company preparing to enter the US botulinum toxin market, adding that with Jeuveau "de-risked from a regulatory standpoint following FDA approval", investor focus will shift to the near-term launch of "frictionless alternative" to market-leading Botox from Allergan (AGN). Gilbert contends that Evolus could carve a "nice slice of this rapidly-growing market".
03/19/19
MZHO
03/19/19
NO CHANGE
Target $29
MZHO
Buy
Evolus price target raised to $29 from $25 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Evolus to $29 from $25 citing lower financing risk and lower share count dilution after the company secured access to a $100M term loan. This event removes a key overhang on the stock, Koffler tells investors in a research note. She reiterates a Buy rating on the shares.
03/11/19
GUGG
03/11/19
NO CHANGE
Target $190
GUGG
Buy
Allergan has 'trapped value,' but unlocking will take time, says Guggenheim
Guggenheim analyst Seamus Fernandez reiterated his Buy rating on Allergan (AGN) shares after Rapastinel's Phase 3 failure, stating that he believes the stock's current price already assumes major challenges and he thinks a major restructuring or sale of the business would be viable options to unlock that value. While Allergan's Botox and aesthetics business is not without risks, such as Revance's (RVNC) long-acting neurotoxin and Evolus' (ELOS) Jeuveau, his analysis suggests Botox and aesthetics are worth $46B-$49B, Fernandez tells investors. As a result of lower pipeline estimates and his base case sum of the parts-based valuation of $170 per share, Fernandez lowered his price target on Allergan shares to $190 from $219.
COTY Coty
$10.85

0.01 (0.09%)

04/17/19
04/17/19
DOWNGRADE
Target $12

Hold
Coty downgraded to Hold from Buy at Stifel
As previously reported, Stifel analyst Mark Astrachan downgraded Coty to Hold and kept his price target at $12, saying the stock is faced with an "increased risk of sustaining modest sales growth and weakening investor confidence in the business turnaround." While the analyst anticipates "only minor residual impact" from supply disruptions on Q3 results, he sees the outlook for Consumer Beauty remaining muted and also points to the company's debt levels and free cash flows limiting its strategic optionality.
04/02/19
SBSH
04/02/19
DOWNGRADE
Target $12
SBSH
Neutral
Coty downgraded to Neutral from Buy at Citi
Citi analyst Wendy Nicholson downgraded Coty to Neutral from Buy and lowered her price target for the shares to $12 from $13. The analyst cites valuation for the downgrade following the stock's year-to-date rally.
04/16/19
04/16/19
UPGRADE
Target $15

Buy
e.l.f. Beauty upgraded to Buy at DA Davidson on increased shelf space presence
As previously reported, DA Davidson analyst Linda Bolton Weiser upgraded e.l.f. Beauty to Buy from Hold and raised her price target to $15 from $7. The analyst cites the findings of her proprietary store checks suggesting that the company products have seen a 17% increase in shelf space at Target (TGT), overtaking Coty's (COTY) Covergirl brand, while its Q1 sales "inflected from down high-single digits" in Q4 to low-single digits. Weiser believes that her FY20 sales forecast of a 2% decline may be conservative based on these findings.
04/17/19
STFL
04/17/19
DOWNGRADE
STFL
Hold
Coty downgraded to Hold from Buy at Stifel
CVE Cenovus Energy
$9.11

-0.285 (-3.04%)

04/16/19
04/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Buy from Hold at Deutsche Bank with analyst Bryan Kraft saying consensus subscriber expectations for both 2019 and 2020 now seem conservative. 2. Cenovus Energy (CVE) upgraded to Neutral from Sell at Goldman Sachs with analyst Neil Mehta citing improvements to the company's leverage outlook and a more constructive commodity price environment, particularly for Canadian heavy crude. 3. Cummins (CMI) upgraded to Buy from Neutral at Citi with analyst Timothy Thein saying he sees upside to 2019 estimates and thinks the company's out-year cash flows "stay higher for longer based on end market diversity and increasing contribution from the aftermarket." 4. Western Digital (WDC) upgraded to Buy from Hold at Deutsche Bank with analyst Sidney Ho starting to see favorable data points in both hard disk drive and NAND that will support a "solid" second half of the year recovery for Western Digital's earnings. 5. e.l.f. Beauty (ELF) upgraded to Buy from Neutral at DA Davidson with analyst Linda Bolton Weiser citing the findings of her proprietary store checks suggesting that the company products have seen a 17% increase in shelf space at Target (TGT), overtaking Coty's (COTY) Covergirl brand, while its Q1 sales "inflected from down high-single digits" in Q4 to low-single digits. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/23/19
SBSH
04/23/19
NO CHANGE
SBSH
Neutral
Citi opens '30-Day Upside Catalyst Watch' on Cenovus Energy
Citi analyst Prashant Rao opened a "30-Day Upside Catalyst Watch" on Neutral-rated Cenovus Energy. Stronger price realizations in the upstream due to higher benchmark oil prices and narrowed Canadian differentials could drive "meaningful upside" to Wednesday's Q1 results, Rao tells investors in a research note. The analyst also sees the potential for upward Q2 estimate revisions, helped by "bullish sentiment" for continued upstream price strength in the near-to-intermediate term.
04/16/19
GSCO
04/16/19
UPGRADE
GSCO
Neutral
Cenovus Energy upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Neil Mehta upgraded Cenovus Energy to Neutral from Sell.
04/16/19
GSCO
04/16/19
UPGRADE
Target $11
GSCO
Neutral
Cenovus Energy upgraded to Neutral with $11 price target at Goldman Sachs
Goldman Sachs analyst Neil Mehta upgraded Cenovus Energy (CVE) to Neutral from Sell and raised his price target for the shares to $11 from $7.50. The analyst cites improvements to the company's leverage outlook and a more constructive commodity price environment, particularly for Canadian heavy crude, for the upgrade. However, he stills see more upside to Buy-rated ConocoPhillips (COP), Canadian Natural Resources (CNQ), Suncor (SU) and Imperial Oil (IMO) among large cap North American oils than Cenovus.
LABD Daily S&P Biotech Bear 3x Shares
$21.93

-0.69 (-3.05%)

UBNT Ubiquiti
$169.26

-0.48 (-0.28%)

11/12/18
FBCO
11/12/18
NO CHANGE
Target $86
FBCO
Neutral
Ubiquiti price target raised to $86 from $79 at Credit Suisse
Credit Suisse analyst Sami Badri raised his price target for Ubiquiti to $86 from $79 following quarterly results. The analyst reiterates a Neutral rating on the shares.
11/12/18
BMOC
11/12/18
NO CHANGE
Target $99
BMOC
Market Perform
Ubiquiti price target raised to $99 from $80 at BMO Capital
BMO Capital analyst Tim Long raised his price target on Ubiquiti to $99 after its "strong" Q1 results that were driven by better than expected sales, margins and earnings. The analyst notes that the performance of the company's Enterprise segment was especially impressive, even though its "Service Provider sales continue to lag and the pressures in South America have shown no signs of subsiding". Long keeps his Market Perform on Ubiquiti in spite of its "encouraging" capital return programs because of the "uncertain impact of China tariffs and the challenged Service Provider end market."
02/11/19
BMOC
02/11/19
NO CHANGE
Target $120
BMOC
Market Perform
Ubiquiti price target raised to $120 from $99 at BMO Capital
BMO Capital analyst Tim Long raised his price target on Ubiquiti to $120 after its Q2 earnings, sales, and margins beat across the board. The analyst states that the Enterprise segment drove much of the revenue outperformance, and the rate of decline in Service Provider business was less than expected. Long keeps his Market Perform rating on the shares however, noting the spike in inventories which may reflect concerns about increased tariffs as well as the company's "lack of visibility into sales drivers".
02/11/19
FBCO
02/11/19
NO CHANGE
Target $103
FBCO
Neutral
Ubiquiti price target raised to $103 from $86 at Credit Suisse
Credit Suisse analyst Sami Badri raised his price target for Ubiquiti to $103 from $86 following quarterly results. The analyst reiterates a Neutral rating on the shares.
QTT Qutoutiao
$7.16

0.34 (4.99%)

04/16/19
SBSH
04/16/19
UPGRADE
Target $14
SBSH
Buy
Qutoutiao upgraded to Buy from Neutral at Citi
Citi analyst Alicia Yap upgraded Qutoutiao to Buy from Neutral while lowering her price target for the shares to $14 from $16. The analyst sees a better risk/reward profile with the shares down 24% since the March 29 secondary offering. Qutoutiao's user numbers were solid in March and possible further collaborations with Taobao merchants and Alibaba's marketing could allow the company to capitalize on user retention, Yap tells investors in a research note
02/15/19
UBSW
02/15/19
DOWNGRADE
Target $13.5
UBSW
Neutral
Qutoutiao downgraded to Neutral from Buy at UBS
UBS analyst Jerry Liu downgraded Qutoutiao to Neutral from Buy, telling investors in a research note that the share price has almost tripled since mid-December, possibly attributable to the strong momentum of the company's user expansion as well as Midu's initial success. Liu, who raised his price target to $13.50 from $11, says Qutoutiao's current price implies 2.8x2019E P/S, which he thinks represents a fair risk-reward balance between its user growth potential and margin pressure.
02/20/19
DBAB
02/20/19
DOWNGRADE
DBAB
Hold
Qutoutiao downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Hanjoon Kim downgraded Qutoutiao to Hold saying the risk/reward is balanced at current share levels.
03/06/19
KEYB
03/06/19
DOWNGRADE
KEYB
Sector Weight
Qutoutiao downgraded to Sector Weight from Overweight at KeyBanc
DXCM DexCom
$120.35

2.01 (1.70%)

05/02/19
JPMS
05/02/19
NO CHANGE
Target $170
JPMS
Overweight
DexCom raised guidance still looks conservative, says JPMorgan
JPMorgan analyst Robbie Marcus believes DexCom posted "another impressive quarter" and that its raised guidance still looks conservative. The analyst lowered his price target for the shares to $170 from $175 with peer multiples moving down year-to-date, but he continues to recommend the name with an Overweight rating.
04/23/19
PIPR
04/23/19
NO CHANGE
PIPR
Piper sees Q1 revenue upside for Inogen, Teleflex, Align Technology
Piper Jaffray analyst Matt O'Brien says his deep dive into the MedTech companies exploring the direct-to-consumer sales channel came up "most compelling" for Inogen (INGN), Teleflex (TFX) and Align Technology (ALGN). Website traffic at these companies is at or near three-year highs and historical trends suggest a high likelihood of revenue upside in Q1, O'Brien tells investors in a research note. The analyst also found DexCom's (DXCM) website traffic to be at three-year highs.
04/29/19
PIPR
04/29/19
NO CHANGE
Target $165
PIPR
Overweight
Piper reiterates Overweight on DexCom after 'robust' teen survey results
There were 8,042 responses to Piper Jaffray's teen survey in February and March, of which 1,707 have diabetes or a member of their household does, analyst JP McKim tells investors in a research note. The survey implies underlying continuous glucose monitoring market growth of close to 58%, says the analyst. Abbott (ABT) reported 70% Libre growth in Q1 and DexCom (DXCM) reports May 1, McKim points out. He expects "continued strong growth" from DexCom following the "robust" survey results and reiterates an Overweight rating on the shares with a $165 price target.
05/01/19
PIPR
05/01/19
NO CHANGE
Target $173
PIPR
Overweight
DexCom price target raised to $173 from $165 at Piper Jaffray
Piper Jaffray analyst JP Kim raised his price target on DexCom to $173 and kept his Overweight rating after its "solid" Q1 results. The analyst notes that while the company's Q1 gross margin of 60% was below his expected 64.5% amid capacity expansion investments, he sees DexCom well positioned for the "inflection" in the Continuous Glucose Monitoring market as it converts away from Blood Glucose Meters. Kim also cites the management's discussion of pharmacy contracts having a 2-3 year time span and expects the company's G7 system tracking to launch next year to be competitive "at any price point."
ACAD Acadia
$25.51

3.4 (15.38%)

02/27/19
PIPR
02/27/19
NO CHANGE
Target $30
PIPR
Overweight
Acadia price target raised to $30 from $25 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target for Acadia Pharmaceuticals to $30 following the company's Q4 results. The analyst expects Nuplazid' "modest" revenue growth to continue as safety concerns "slowly subside." She also anticipates a beneficial impact to 2019 sales from the ongoing direct-to-consumer campaign. As such, the company's fiscal 2019 guidance of $275M-$300M "appears in line and readily achievable," Brill tells investors in a post-earnings research note. With Acadia beginning two Phase 3 major depressive disorder trials in the first half of 2019, the analyst expects the shares to start reflecting value for the indication as the program continues to advance. She introduced probability-adjusted numbers at a 25% chance of success into her model and keeps an Overweight rating on Acadia.
02/27/19
ADAM
02/27/19
NO CHANGE
Target $27
ADAM
Hold
Canaccord says Acadia shares 'getting interesting,' raises price target to $27
Canaccord analyst Sumant Kulkarni said Acadia reported decent Q4 results, with Nuplazid sales coming in in-line with expectations. The outlook was solid, suggesting the media issues the drug faced are behind it, which is encouraging, said Kulkarni. With that out of the way, the analyst believes the stock is getting more interesting heading into data readouts for the company's dementia and schizophrenia drugs. Kulkarni maintained his Hold rating and raised his price target to $27 from $23 on Acadia shares.
12/10/18
ADAM
12/10/18
INITIATION
Target $23
ADAM
Hold
Acadia initiated with a Hold at Canaccord
Canaccord analyst Sumant Kulkarni initiated Acadia Pharmaceuticals with a Hold rating and $23 price target. In a research note to investors, Kulkarni says that while he believes Acadia is a core holding for investors seeking exposure to central nervous system, or CNS, companies with commercial assets, he believes the risk/reward on the stock is balanced ahead of potential issuance of the company's initial 2019 outlook for Nuplazid in Parkinson's Disease psychosis, or PDP, and views his sales estimate for Nuplazid as "reasonable," though he admits he has low visibility heading into the event.
05/01/19
PIPR
05/01/19
NO CHANGE
Target $35
PIPR
Overweight
Acadia price target raised to $35 from $30 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target on Acadia to $35 and kept her Overweight rating after its better than expected Q1 sales of Nuplazid that was driven by "accelerated growth in new patient starts." The analyst further cites the management's increased FY19 Nuplazid midpoint sales guidance and also sees "significant unrealized value" for the company's dementia related psychosis programs.
CRSP Crispr Therapeutics
$40.35

0.46 (1.15%)

04/11/19
EVER
04/11/19
INITIATION
Target $46
EVER
Outperform
Crispr Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Crispr Therapeutics with an Outperform rating and a price targets of $46. The analyst says the company's ex vivo gene therapy gives it a low risk path to market while it continues to refine its delivery systems required for in vivo editing. Mehrotra also cites Crispr's potential to have several programs in clinic in 2019-2020, along with strong partnerships and clinical execution that "could lead to significant near term clinical news flow."
04/16/19
PIPR
04/16/19
NO CHANGE
Target $75
PIPR
Overweight
Piper reiterates $75 target for Crispr after CTX001 gets Fast Track
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics after the company and partner Vertex (VRTX) announced Fast Track Designation for CTX001 to treat transfusion-dependent beta thalassemia. The analyst believes Crispr's ex vivo approach and biological rational of targeting fetal hemoglobin "de-risk and differentiate" CTX001 from other gene editing players. And he continues to think that first-in-man CTX001 data this year "will serve as an important driver" for Crispr and the gene editing field. Tenthoff says Crispr Therapeutics remains a top for 2019.
04/22/19
BTIG
04/22/19
NO CHANGE
BTIG
Buy
BTIG raises price targets on Editas Medicine, CRISPR Therapeutics
BTIG analyst Amanda Murphy raised her price target on Buy-rated Editas Medicine (EDIT) to $33 from $30 and CRISPR Therapeutics (CRSP) to $49 from $43 as part of her first installment of a broader research note analyzing hiring trends in the gene therapy space. The analyst notes that the latter is "aggressively adding process development/CMC/Tech capabilities in cell therapy, including late stage process development resources", which may suggest that the company is "farther along" in the development of CTX110. Murphy also observes that Editas Medicine appears to be "shifting focus to engineered stem cell therapy while still investing in allo CAR-T and potentially new in vivo indications and delivery vectors."
04/30/19
PIPR
04/30/19
NO CHANGE
Target $75
PIPR
Overweight
Crispr Therapeutics remains a top pick for 2019 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Crispr Therapeutics remains a top pick for 2019 following the company's Q1 results. The company has a cash position of $456M its Phase I/II study of CTX001 in transfusion-dependent beta thalassemia is "on-going," which suggests the first patient has successfully engrafted representing a "significant milestone," Tenthoff tells investors in a research note. He expects "first-in-man data" from both Phase I/II studies later this year to "serve as a major driver" and reiterates an Overweight rating on the stock with a $75 price target.

TODAY'S FREE FLY STORIES

03:00
07/22/19
07/22
03:00
07/22/19
03:00
General news
FX Update: The dollar has remained underpinned »

FX Update: The dollar has…

02:05
07/22/19
07/22
02:05
07/22/19
02:05
General news
Asian Market Wrap: »

Asian Market Wrap:…

ASOMY

Asos

$0.00

(0.00%)

21:13
07/21/19
07/21
21:13
07/21/19
21:13
Downgrade
Asos rating change at JPMorgan »

Asos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$131.95

-1.5 (-1.12%)

21:12
07/21/19
07/21
21:12
07/21/19
21:12
Upgrade
KLA-Tencor rating change at Goldman Sachs »

KLA-Tencor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

LRCX

Lam Research

$198.43

0.19 (0.10%)

21:07
07/21/19
07/21
21:07
07/21/19
21:07
Upgrade
Lam Research rating change at Goldman Sachs »

Lam Research upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MRVL

Marvell

$25.90

-0.48 (-1.82%)

21:07
07/21/19
07/21
21:07
07/21/19
21:07
Downgrade
Marvell rating change at Goldman Sachs »

Marvell downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$47.79

-0.38 (-0.79%)

21:05
07/21/19
07/21
21:05
07/21/19
21:05
Upgrade
Applied Materials rating change at Goldman Sachs »

Applied Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$45.51

0.85 (1.90%)

21:04
07/21/19
07/21
21:04
07/21/19
21:04
Upgrade
Goldman Sachs more positive on memory stocks, upgrades Micron to Buy »

Goldman Sachs analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEYS

Keysight Technologies

$87.43

0.05 (0.06%)

20:49
07/21/19
07/21
20:49
07/21/19
20:49
Downgrade
Keysight Technologies rating change at Goldman Sachs »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYND

Beyond Meat

$176.65

6.28 (3.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

19:30
07/21/19
07/21
19:30
07/21/19
19:30
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

BYND

Beyond Meat

$176.65

6.28 (3.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

DIS

Disney

$139.86

-1.76 (-1.24%)

NFLX

Netflix

$315.10

-10.04 (-3.09%)

T

AT&T

$32.77

-0.32 (-0.97%)

CBS

CBS

$50.68

-0.66 (-1.29%)

FDX

FedEx

$167.08

1.69 (1.02%)

EFX

Equifax

$137.29

-2 (-1.44%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

V

Visa

$179.18

-1.34 (-0.74%)

PYPL

PayPal

$118.65

-1.22 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 12

    Aug

  • 21

    Aug

  • 29

    Aug

  • 17

    Sep

  • 19

    Sep

  • 25

    Sep

  • 16

    Oct

  • 13

    Nov

T

AT&T

$32.77

-0.32 (-0.97%)

, CMCSA

Comcast

$44.06

-0.5 (-1.12%)

18:23
07/21/19
07/21
18:23
07/21/19
18:23
On The Fly
Box Office Battle: 'The Lion King' roars to number 1 in $185M U.S. debut »

"Box Office Battle" is…

T

AT&T

$32.77

-0.32 (-0.97%)

CMCSA

Comcast

$44.06

-0.5 (-1.12%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$53.68

-0.275 (-0.51%)

LGF.A

Lionsgate

$11.94

0.36 (3.11%)

DIS

Disney

$139.86

-1.76 (-1.24%)

VIAB

Viacom

$30.48

-0.11 (-0.36%)

VIA

Viacom

$35.24

0.24 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

EFX

Equifax

$137.29

-2 (-1.44%)

17:23
07/21/19
07/21
17:23
07/21/19
17:23
Periodicals
Equifax agrees to pay $700M after massive data breach, WSJ reports »

Equifax is nearing a deal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

  • 12

    Aug

  • 13

    Nov

CBS

CBS

$50.68

-0.66 (-1.29%)

, T

AT&T

$32.77

-0.32 (-0.97%)

17:17
07/21/19
07/21
17:17
07/21/19
17:17
Periodicals
AT&T drops CBS channels from cable systems, Reuters reports »

CBS (CBS) and AT&T…

CBS

CBS

$50.68

-0.66 (-1.29%)

T

AT&T

$32.77

-0.32 (-0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

  • 08

    Aug

NFLX

Netflix

$315.10

-10.04 (-3.09%)

17:11
07/21/19
07/21
17:11
07/21/19
17:11
Periodicals
Netflix signs first direct agreement with SAG-AFTRA, Bloomberg reports »

Netflix and the Screen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

17:08
07/21/19
07/21
17:08
07/21/19
17:08
Periodicals
Johnson & Johnson facing key test in talc-safety lawsuits, WSJ reports »

Johnson & Johnson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

MRKR

Marker Therapeutics

$6.28

-2.4 (-27.65%)

16:46
07/21/19
07/21
16:46
07/21/19
16:46
Hot Stocks
Marker Therapeutics reports interim results of MultiTAA T Cell Therapy »

Marker Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 09

    Sep

RDY

Dr. Reddy's

$37.73

-0.6 (-1.57%)

16:41
07/21/19
07/21
16:41
07/21/19
16:41
Hot Stocks
Dr. Reddy's announces transaction closure to divest Zembrace Symtouch, Tosymra »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

KLAC

KLA-Tencor

$131.95

-1.5 (-1.12%)

16:37
07/21/19
07/21
16:37
07/21/19
16:37
Upgrade
KLA-Tencor rating change at Goldman Sachs »

KLA-Tencor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

LRCX

Lam Research

$198.43

0.19 (0.10%)

16:33
07/21/19
07/21
16:33
07/21/19
16:33
Upgrade
Lam Research rating change at Goldman Sachs »

Lam Research upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MRVL

Marvell

$25.90

-0.48 (-1.82%)

16:30
07/21/19
07/21
16:30
07/21/19
16:30
Downgrade
Marvell rating change at Goldman Sachs »

Marvell downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEYS

Keysight Technologies

$87.43

0.05 (0.06%)

16:29
07/21/19
07/21
16:29
07/21/19
16:29
Downgrade
Keysight Technologies rating change at Goldman Sachs »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$45.51

0.85 (1.90%)

16:26
07/21/19
07/21
16:26
07/21/19
16:26
Upgrade
Micron rating change at Goldman Sachs »

Micron upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.